ClinicalTrials.gg
Not yet recruitingNCT07140055Updated Aug 24, 2025

A Research Study to Evaluate BLX-7006 in Healthy Adults

A Phase 1 interventional study of BLX-7006 and Placebo in Normal Healthy Volunteer and Safety After Oral Intake, sponsored by Biolexis Therapeutics. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Biolexis Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
109th of 168
76 · median 184
Started
2025
with 24 others
Phase 1
32 of 187
14 open now
Primary completion
2026-04
later than 8 of 73 live
Registered
138th of 187
by date

Among the 187 studies in Obesity with a site in Australia, this one is the 109th largest by planned enrollment of the 168 interventional ones that give a count, is one of 25 that started in 2025, is one of 32 in phase 1, reaches primary completion later than 8 of the 73 other live ones, and was the 138th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 187 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.

Read the detailed description

This is a Phase 1, single-center, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the effect of food on the PK of BLX-7006, a novel oral small-molecule GLP-1 receptor agonist, in healthy adult volunteers. The study consists of three parts: single ascending dose (SAD), food effect (FE), and multiple ascending dose (MAD) assessments.

Study Rationale and Objectives:

BLX-7006 is being developed as an oral alternative to currently available injectable GLP-1 receptor agonists used for the treatment of metabolic diseases such as type 2 diabetes mellitus and obesity. Oral delivery of BLX-7006 may improve convenience and treatment adherence while maintaining the metabolic benefits of GLP-1 agonism. This Phase 1 study is designed to characterize the initial safety profile, define the PK properties of BLX-7006, evaluate preliminary PD biomarkers of glucose metabolism, and determine the impact of a high-fat meal on drug absorption.

Study Design Overview:

The study will enroll approximately 76 healthy adults across three sequential parts.

Part 1: Single Ascending Dose (SAD) This is a randomized, double-blind, placebo-controlled, sequential SAD study in up to four cohorts (approximately 8 participants per cohort; 6 active, 2 placebo). Doses will escalate sequentially following review of blinded safety, tolerability, PK, and PD data by a Safety Review Committee (SRC). A sentinel dosing approach will be used for each cohort (1 active, 1 placebo) prior to dosing the remainder of the cohort. Participants will be confined in the clinical research unit (CRU) for approximately 4 days for safety monitoring, PK and PD blood sampling, and will return for an end-of-study (EOS) visit on Day 8. SAD data will inform dose selection for the FE and MAD parts of the study.

Part 2: Food Effect (FE) This is an open-label, randomized, 2-period, 2-sequence crossover study designed to evaluate the effect of a high-fat, high-calorie meal on the PK of a single oral dose of BLX-7006. A single cohort of 12 participants will receive BLX-7006 under both fasted and fed conditions, with a 7-day washout between doses. Participants will be confined for approximately 4 days in each period, with safety, PK, and PD assessments performed throughout. The SRC may adjust the washout interval or timing of assessments based on PK results from the SAD cohorts to ensure adequate elimination between periods.

Part 3: Multiple Ascending Dose (MAD) This is a randomized, double-blind, placebo-controlled, sequential MAD study in up to four cohorts (approximately 8 participants per cohort; 6 active, 2 placebo). Participants will receive BLX-7006 or placebo orally once daily for 7 days. Participants will be confined from Day -1 through approximately Day 10 for dosing, safety assessments, and PK/PD sampling, with an EOS visit on Day 14. Dose escalation to subsequent MAD cohorts will occur following review of blinded safety, PK, and PD data by the SRC.

Safety Monitoring:

Safety will be evaluated throughout the study by monitoring adverse events (AEs), clinical laboratory tests, vital signs, 12-lead electrocardiograms (ECGs), and physical examinations. Sentinel dosing and SRC reviews between cohorts are incorporated to minimize risk.

Pharmacokinetic and Pharmacodynamic Assessments:

Blood samples will be collected to characterize single- and multiple-dose PK parameters of BLX-7006, including maximum concentration (Cmax), time to maximum concentration (Tmax), area under the curve (AUC), half-life (t½), and apparent clearance. PD endpoints will include biomarkers of glucose metabolism and insulin production. The FE part will compare PK parameters between fasted and fed states.

Dose Escalation and Cohort Progression:

The SRC will review cumulative safety, tolerability, PK, and PD data after each cohort before escalating to the next dose level. The number of cohorts may be reduced based on emerging data. The FE and MAD parts may proceed in parallel with later SAD cohorts once predefined safety criteria are met.

The results of this study will provide the initial clinical safety and PK/PD profile of BLX-7006, including preliminary assessment of food effect, to support future clinical development in populations with metabolic diseases.

03

Conditions studied

  • Normal Healthy Volunteer
  • Safety After Oral Intake

Keywords

  • Obesity
  • Type 2 Diabetes
  • Metabolic Disorders
  • Normal Healthy Volunteer
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females, 18-65 years, 20-35 kilograms/meter² (kg/m²), weight ≥50 kilograms (kg).
  • Normal or clinically acceptable labs, vital signs
  • \<6.5%, non-fasting glucose 4.0-7.8 milimol/Liter (mmol/L)
  • Willing to follow requirements, avoid alcohol, nicotine, and blood donation per protocol, and comply with all study visits and procedures.

Exclusion criteria

Exclusion Criteria:

  • History of diabetes, cardiovascular, hepatic, renal, gastrointestinal, psychiatric, or neurologic disease, or abnormal labs/Echocardiograms () deemed clinically relevant.
  • Prior gastrointestinal (GI) surgery affecting absorption (e.g., gastric bypass) or chronic GI disorders.
  • History or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2); within 5 years (except treated basal cell or in situ cervical cancer).
  • History of severe allergic reactions, seizures, or psychiatric hospitalization; positive drug, alcohol, or cotinine test.
  • Use of prescription drugs, Over the counter (OTC) /herbal supplements
  • Participation in another clinical trial or blood donation within 30 days (or 5 half-lives of prior drug).
  • Any condition or history that may compromise safety, study conduct, or compliance, in the opinion of the Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    BLX-7006 Oral Dose

    Participants will receive oral BLX-7006 as a single dose (in Part 1 or 2) or once daily for 7 days (in Part 3).

    Drug: BLX-7006

  • Placebo comparator
    Placebo to match BLX-7006

    Participants will receive an oral placebo that looks like BLX-7006 but does not contain active drug as a single dose (in Part 1 or 2) or once daily for 7 days (in Part 3).

    Drug: Placebo

Interventions

  • DrugBLX-7006

    BLX-7006 Single or Multiple doses administered orally as a tablet

  • DrugPlacebo

    Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.

06

What researchers measure

Primary outcomes

  1. Number of participants who experienced Adverse Events (AEs)

    The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of adverse effects in subjects, as assessed according to CTCAE v5.0. The number of participants who experience an AE will be reported.

    Time frame: From first dose through End of Study (up to ~28 days per participant)

  2. Number of participants who experienced Serious Adverse Events (SAEs)

    The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of SAE in subjects, as assessed according to CTCAE v5.0. The number of participants who experience a SAE will be reported.

    Time frame: From first dose through End of Study (up to ~28 days per participant)

  3. Number of participants who experienced Treatment-Related Adverse Avents (TRAEs)

    The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of TRAEs in subjects, as assessed according to CTCAE v5.0. The number of participants who experience a TRAE will be reported.

    Time frame: From first dose through End of Study (up to ~28 days per participant)

Secondary outcomes

  1. Assess maximum observed drug concentration (Cmax)

    Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults

    Time frame: Up to 14 days after last dose in each cohort

  2. Assess time to maximum concentration (Tmax)

    Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults

    Time frame: Up to 14 days after last dose in each cohort

  3. Assess the area under the concentration-time curve from time 0 to infinity (AUCinf)

    Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults

    Time frame: Up to 14 days after last dose in each cohort

  4. Assess the area under the concentration curve from time 0 to the last quantifiable concentration (AUClast)

    Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults

    Time frame: Up to 14 days after last dose in each cohort

  5. Assess half-life (t½) plasma concentration

    Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults

    Time frame: Up to 14 days after last dose in each cohort

  6. Serum fructosamine levels

    Evaluate the effect of single and multiple oral doses of BLX-7006 on serum fructosamine levels

    Time frame: Up to 14 days after last dose in each cohort

  7. Insulin levels

    Evaluate the effect of single and multiple oral doses of BLX-7006 on insulin levels

    Time frame: Up to 14 days after last dose in each cohort

  8. C-peptide levels

    Evaluate the effect of single and multiple oral doses of BLX-7006 on C-peptide levels

    Time frame: Up to 14 days after last dose in each cohort

  9. Glucagon levels

    Evaluate the effect of single and multiple oral doses of BLX-7006 on glucagon levels

    Time frame: Up to 14 days after last dose in each cohort]

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Apr 2026, 7 months later.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 7 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 24, 2025
StartEst.
Sep 2025
Primary completionEst.
Apr 2026
CompletionEst.
May 2026
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07140055
Lead sponsor
Biolexis Therapeutics
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Sep 2025 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Aug 24, 2025

Study contacts

Jeremiah James Bearss, MD, PhD
Contact
jbearss@biolexistx.com
(385) 476-3080
Matthew Anthony, BS, BS
Contact
manthony@biolexistx.com
(385) 476-3080

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion